BB&T Securities LLC decreased its stake in Mednax, Inc (NYSE:MD) by 78.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,907 shares of the company’s stock after selling 369,596 shares during the period. BB&T Securities LLC owned 0.11% of Mednax worth $6,212,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its stake in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock valued at $139,000 after buying an additional 1,794 shares during the last quarter. Morgan Dempsey Capital Management LLC boosted its stake in shares of Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock valued at $158,000 after buying an additional 102 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Mednax by 8.7% in the first quarter. Daiwa Securities Group Inc. now owns 2,500 shares of the company’s stock valued at $173,000 after buying an additional 200 shares during the last quarter.

Shares of Mednax, Inc (NYSE MD) opened at 42.27 on Monday. The firm has a 50-day moving average price of $51.66 and a 200-day moving average price of $60.50. The firm has a market capitalization of $3.90 billion, a PE ratio of 13.46 and a beta of 0.40. Mednax, Inc has a 1-year low of $41.52 and a 1-year high of $72.13.

Mednax (NYSE:MD) last issued its quarterly earnings data on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.04. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The firm had revenue of $843 million for the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the previous year, the business posted $1.03 EPS. The firm’s revenue was up 9.2% compared to the same quarter last year. On average, analysts forecast that Mednax, Inc will post $3.31 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/21/mednax-inc-md-shares-sold-by-bbt-securities-llc.html.

Several brokerages have recently issued reports on MD. Mizuho reduced their price objective on Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 30th. Jefferies Group LLC reiterated a “hold” rating and issued a $58.00 price objective on shares of Mednax in a research note on Wednesday, April 26th. TheStreet cut Mednax from a “b-” rating to a “c+” rating in a research note on Tuesday, May 16th. BidaskClub upgraded Mednax from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $55.00 to $68.00 in a research note on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $63.00.

In other news, insider Joseph M. Calabro sold 23,327 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now owns 296,379 shares in the company, valued at approximately $16,300,845. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the sale, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.